E2F6: A Drug Target / Disease Biomarker (G1876)

Target Name: E2F6

NCBI ID: G1876

E2F6

E2F6: A Drug Target / Disease Biomarker

E2F6 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a key regulator of the cell cycle, and is involved in the process of cell division and growth. Mutations in the E2F6 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, E2F6 has emerged as a promising drug target for a variety of diseases.

One of the key features of E2F6 is its role in regulating the cell cycle. The cell cycle is the process by which a cell grows, replicates its DNA, and divides. E2F6 is involved in the regulation of the length of the S phase of the cell cycle, which is the stage of the cell cycle at which the DNA is replicated.

Mutations in the E2F6 gene have been linked to various diseases, including cancer. For example, studies have shown that E2F6 mutations are associated with an increased risk of pancreatic cancer. Additionally, E2F6 mutations have also been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its role in cell division and growth, E2F6 is also involved in the regulation of the cell signaling pathway. This pathway is responsible for transmitting signals from the cell surface to the inside of the cell, and is critical for the function of many different cellular processes. E2F6 is involved in the regulation of several key signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway.

E2F6 has also been shown to play a role in the regulation of cellular adhesion. Adhesion is the process by which cells stick together and form tissues. E2F6 is involved in the regulation of cell-cell adhesion, as well as cell-cell tightening. This is important for the development and maintenance of tissues and organs, and is a critical aspect of many diseases.

In addition to its role in cell signaling and division, E2F6 is also involved in the regulation of cellular stress. Stress can cause damage to cells, and E2F6 is involved in the regulation of the cellular stress response. This is important for the survival of cells in response to various stressors, and is a critical aspect of many diseases.

Overall, E2F6 is a protein that is involved in a wide range of cellular processes that are important for the development and maintenance of tissues and organs. As a result, E2F6 has emerged as a promising drug target for a variety of diseases. Further research is needed to fully understand the role of E2F6 in these processes, and to develop effective treatments for the diseases associated with E2F6 mutations.

Protein Name: E2F Transcription Factor 6

Functions: Inhibitor of E2F-dependent transcription (PubMed:9689056, PubMed:9704927, PubMed:9501179). Binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' (PubMed:9501179). Has a preference for the 5'-TTTCCCGC-3' E2F recognition site (PubMed:9501179). E2F6 lacks the transcriptional activation and pocket protein binding domains (PubMed:9704927, PubMed:9501179). Appears to regulate a subset of E2F-dependent genes whose products are required for entry into the cell cycle but not for normal cell cycle progression (PubMed:9689056, PubMed:9501179). Represses expression of some meiosis-specific genes, including SLC25A31/ANT4 (By similarity). May silence expression via the recruitment of a chromatin remodeling complex containing histone H3-K9 methyltransferase activity. Overexpression delays the exit of cells from the S-phase (PubMed:9501179)

The "E2F6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about E2F6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets